Screening for Gestational Diabetes Mellitus: Challenges and Controversies
Gestational diabetes mellitus (GDM) is associated with several adverse outcomes for the fetus, newborn, and mother. Screening for and diagnosing GDM is accomplished through oral glucose tolerance testing. The American College of Obstetricians and Gynecologists (ACOG) has long advocated for a two-step testing approach that incorporates a screening test followed by a diagnostic test for those women who have a positive screening test. Recently, the International Association of Diabetes in Pregnancy Study Groups (IADPSG) has recommended that a simplified one-step testing approach be used to screen and diagnose GDM based on the results of the Hyperglycemia and Adverse Outcomes (HAPO) study. Although this approach has been adopted by the American Diabetes Association (ADA), considerable controversy remains regarding which approach is best. This program will review the different guidelines and recommendations as they relate to the diagnosis of GDM.
Originally presented December 27, 2012 in Salt Lake City, Utah.
David G. Grenache, PhD
Medical Director, Special Chemistry Laboratory, ARUP Laboratories
Assistant Professor of Pathology, University of Utah School of Medicine
Dr. Grenache is the director of the Special Chemistry Laboratory at ARUP and is a certified diplomate by the American Board of Clinical Chemistry. Dr. Grenache earned his PhD from Worcester Polytechnic Institute in Worcester, Massachusetts and completed a clinical chemistry fellowship at Washington University, St. Louis.
After this presentation, participants will be able to:
- Describe the risk factors and adverse outcomes associated with GDM.
- Explain the objective and results of the HAPO study.
- Compare and contrast recommendations for screening and diagnosing GDM.
University of Utah School of Medicine and ARUP Laboratories